Clinical

Panelists discuss how payers typically require step therapy with SGLT2 inhibitors before approving nonsteroidal MRAs due to cost considerations, while acknowledging the need for head-to-head trials to determine incremental benefits, though early clinical experience suggests good tolerability and the potential for combination therapy initiation rather than sequential treatment approaches.

Panelists discuss how nonsteroidal MRAs like finerenone differ mechanistically from steroidal MRAs by lacking steroid rings (reducing steroid-related adverse effects like gynecomastia), having different mineralocorticoid receptor binding patterns, shorter half-lives, and potentially lower hyperkalemia risk, with strong evidence supporting their use in heart failure with preserved ejection fraction and additive benefits when combined with SGLT2 inhibitors.

Eosinophilia serves as a significant biomarker for predicting immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors.

Prioritizing education and shared decision-making can help patients with newly diagnosed heart failure feel less overwhelmed, said Martha Gulati, MD.

Sotatercept can enhance treatment for pulmonary arterial hypertension, even in patients already on conventional therapies, said Vallerie McLaughlin, MD.

The oral PCSK9 inhibitor enlicitide can change cholesterol management with high efficacy and improved adherence, said Ann Marie Navar, MD, PhD.

In a phase 3 trial, the investigational oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by nearly 60% in adults with or at risk for ASCVD.

Brensocatib improves lung structure and reduces exacerbations in non-cystic fibrosis bronchiectasis with or without COPD, according to posters presented at this year's CHEST meeting.

Panelists discuss how real-world programs like PROMPT-LIPID expose undertreatment patterns and guide care improvement.

Panelists discuss how pharmacy-related delays and limited escalation practices widen LDL-C management gaps.

Oncology experts at PCOC 2025 discuss breakthrough therapies, AI-driven care, and evolving care delivery models shaping the future of oncology.

The efficacy of immune checkpoint inhibitors was found in patients with both HIV and non–small cell lung cancer (NSCLC), though more inclusion of people with HIV is needed in future studies.

Remibrutinib shows promise in treating generalized myasthenia gravis, with ongoing trials assessing its efficacy and safety for patients.

Patients save most on outpatient surgeries at in-network sites, so Xiaoxi Zhao, PhD, emphasizes that transparency could help them make better cost choices.

For Medicaid care management, focusing on rising-risk patients is more effective than targeting high-cost claimants, whose spending tends to decrease over time due to regression to the mean.

Experts discuss the complexities of treatment sequencing in cancer therapy, emphasizing the importance of using the best therapies upfront for optimal outcomes.

Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.

Experts analyze how Trump's drug pricing policies, including Most Favored Nation (MFN) and tariffs, reshape pharma markets and impact patient costs and access.

Speakers at AMCP Nexus 2025 reviewed the oncology pipeline, highlighting expanded indications and new therapies advancing innovation, access, and value.

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment.

Patients with diabetic macular edema (DME) using faricimab had durable results after 1 year in real-world practice.

Clinicians may underassess the need for community-based palliative care among patients with dementia.

Panelists discuss how RWE informs treatment and safety decisions for special populations such as patients with ECOG PS 2 with metastatic colorectal cancer.

Panelists discuss how PROs, particularly tolerability and fatigue, guide shared decision-making for third-line therapy in mCRC.

In-network ambulatory surgery centers are cheapest, while out-of-network hospital outpatient departments nearly double costs, says Xiaoxi Zhao, PhD.